Insider filing
Traded Nov 4 · filed 2 days later
Compensation award — excluded from discretionary-purchase analysis.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Oct 14, 2026 · Filed Oct 15, 2026
The CEO of Crispr Therapeutics sold $202K of Crispr Therapeutics shares. The filing references tax withholding.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$201,867
Shares × reported transaction price
72 days after results of Aug 3, 2026, 19 days before results of Nov 2, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $50.22 on Oct 14, 2026, 13% above its 52-week low and 32% below its high, after a 12% drop over the previous 30 trading days
52-week range $44.34 (Mar 30, 2026) to $73.97 (Oct 20, 2025), 20% of the way up, from 250 adjusted closes. 30 trading days earlier: $56.98 on Aug 31, 2026. Describes the past only, not a forecast
RSI 40, 5% under its 200-day average, 9% under its 50-day average, 32% below the 52-week high, 20-day volatility 61% a year, against the S&P 500: −5 points over 1 month, −4 points over 3 months, −22 points over 6 months
From the adjusted closes up to Oct 14, 2026. RSI: Wilder's 14-day relative strength index (0 to 100). Averages: the last 50 and 200 closes. Volatility: standard deviation of the last 20 daily returns, annualised. S&P 500: the stock's move minus SPY's between the same dates (21, 63 and 126 trading days). Describes the past only, not a forecast
Footnote references tax withholding
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +0.3% | −0.4% | +0.7% |
| 30 days | −18.0% | −3.0% | −15.0% |
Past results only. Not a forecast.
Insider filing
Traded Nov 4 · filed 2 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Nov 4 · filed 2 days later
Compensation award — excluded from discretionary-purchase analysis.
Raju Prasad (Officer) plans to sell ~$3.96M of Crispr Therapeutics
Planned, from payEvery dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.